Manufacturing Equipment, Biologics

Collaboration between equipment suppliers and users is leading to innovation and optimization in biopharmaceutical manufacturing.

Cytiva’s new facility in Shrewsbury, MA will make equipment such as single-use bioreactors.

The investment will expand and upgrade manufacturing capacity and technology for pre-fillable syringes and will also includes a new manufacturing facility in Europe.

Pharmaceutical Technology spoke with Tania Pereira Chilima, Deputy CTO at Univercells Technologies about their technology and how it can be used in viral vector manufacturing, which is needed for production of some of the COVID-19 vaccine candidates.

The new super plant, being built in Incheon, South Korea, will have a total biopharmaceutical manufacturing capacity of 256,000 L.

The agreement follows a recent announcement that Sartorius plans to invest $100 million in Songdo, South Korea’s bio cluster.

Sanofi’s Digitally Enabled Integrated Continuous Biomanufacturing Facility in Framingham, MA was named the Overall Award winner at the ISPE virtual annual meeting.

Automation, digitalization, and supply-chain strategies help mitigate vulnerabilities in both autologous and allogeneic cell therapy manufacturing.

The new facility at the company’s San Diego, CA, site will be for late phase and commercial CGMP manufacturing.

Cytiva will provide the first FlexFactory to be used in the manufacture of pDNA to Akron Bio.

Facility and equipment design are important, but the team and its experience matter most.

The investment will include new manufacturing lines and increased automation to deliver additional manufacturing capacity.

The company is investing $130 million to add Phase III through commercial-scale manufacturing suites to its gene therapy campus in Harmans, MD.

A new approach to testing water content in biologics is needed that will give a more accurate determination of actual water content in the biologic.

The company has made several moves in recent weeks to expand manufacturing capacity and cell line services.

The VIA Capsule from Cytiva is a liquid nitrogen-free cryogenic shipment system designed to transport cell therapies.

Ori Biotech is partnering with manufacturers and materials suppliers to develop an automated system for cell and gene therapy manufacturing.

Single-use processing requires instruments providing the accuracy of traditional technologies but configured in form factors designed specifically for this service

Bioprocessing advances improve product yield, cut costs, and streamline integration between upstream and downstream processes.

The ASTM standard describes how to evaluate single-use systems for foreign particle analysis.

The new BIOSTAT STR Generation 3 with BIOBRAIN bioproduction platform offers process intensification with automated feed and bleed and integrated cell retention functionality.

GE Healthcare Life Sciences will supply Akeso Pharmaceuticals with the FlexFactory platform to accelerate production of antibody drugs in the Guangzhou region.

GE Healthcare Life Sciences’ KUBio box is an integrated, flexible biomanufacturing environment for viral vector-based gene therapies.

The company’s Custom Single Run product line now has available bioreactors with working volumes of up to 6000 L.

The Birtley, UK facility added cleanroom, manufacturing, and testing facilities for biopharma manufacturing single-use systems.

Sartorius Stedim Biotech has unveiled a new single-use vessel for its ambr 250 modular benchtop automated mini bioreactor system that has been specifically designed for therapeutic cell lines.

The $10-million investment will include a 500-L single-use perfusion bioreactor and seven patented downstream processing units.

Sartorius Stedim Biotech’s Generation 2 ambr 15 cell culture microbioreactor system offers increased flexibility and expanded capability for clone selection, media and feed optimization, and early process development work.

The expansion will increase the company’s single-use capacity to meet growing demand.

Vibalogics has increased its single-use bioreactor and purification capacity with a new manufacturing for its specialist oncolytic virus and viral vector manufacturing services as a result of a growth in demand.